- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474212
: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, randomized, controlled trial. After informed consent, 80 elective on pump CABG patients with a clinical indication for post-operative thromboprophylaxis will be studied in the Tampere University Heart Hospital. Study has two independent parts with 40 patients in both. Results are reported separately from these two parts of the study.
Firts part of the study: After written consent, 20+20 patients are randomized to receive enoxaparin either as continuous intravenous infusion (treatment group) or subcutaneous bolus injection (control group). Enoxaparin dose is 40mg/24h either CIV of SCB. Anti-Xa values are measured 12-14 times from blood samples to evaluate the anticoagulation effect of enoxaparin.
Second part of the study: After written consent, 20+20 patients are randomized to receive enoxaparin either as continuous intravenous infusion (treatment group) or subcutaneous bolus injection (control group). Enoxaparin dose is 1mg/kg/24h in CIV group and 0,5mg/kg twice a day in SCB group. In this second part of the study with eleveted enoxaparin dosage, 4 additional blood samples will be taken and analysed by ROTEM to investigate the overall coagulation status of the patients before and after the initiation of enoxaparin.
The study will consist of two independent parts.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Kati Järvelä, PhD
- Phone Number: +358331164869
- Email: kati.jarvela@sydansairaala.fi
Study Contact Backup
- Name: Maria Parviainen, MD
- Email: maria.parviainen@tuni.fi
Study Locations
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Finland, 33521
- Tampere university Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI between 18-33 kg/m2
- Elective on-pump CABG operation
- Indication for post-operative pharmacological thromboprophylaxis
- Written informed consent obtained from the patient or his/her legal representative.
Exclusion Criteria:
- Other indications for anticoagulant therapy than thromboprophylaxis
- Known heparin induced thrombocytopenia (HIT), or hypersensitivity to enoxaparin or heparin
- Any long-term anticoagulant medication, expect low-dose aspirin
- Major bleeding within the last week unless definitively treated
- Blood platelet count <20, P-TT <20 % or INR >1.7
- GFR less than 30 ml/min/1.73 m2 estimated from serum creatinine by applying Cockcroft-Gault equation 13 or chronic dialysis
- Known HIV, HBV, or HCV infection
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Enoxaparin 40 mg s.c.
Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
|
|
Active Comparator: Enoxaparin 40 mg i.v.
Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
|
|
Active Comparator: Enoxaparin 0.5 mg/kg s.c.
Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
|
|
Active Comparator: Enoxaparin 1 mg/kg i.v.
Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-Xa concentration maximum 0-24h (Cmax0-24h)
Time Frame: 0-24h after initiation of enoxaparin
|
Anti-Xa concentration maximum level calculated from measured values during 0-24h after initiation of enoxaparin.
|
0-24h after initiation of enoxaparin
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-Xa concentration maximum 25-72 h (Cmax25-72h)
Time Frame: 25-72 h after initiation of enoxaparin
|
Anti-Xa concentration maximum level calculated from measured values 25-72h after the initiation of enoxaparin.
|
25-72 h after initiation of enoxaparin
|
Anti-Xa trough concentartion at 72 h (C72h)
Time Frame: 72 h after the initiation of enoxaparin
|
Anti-Xa concentration at the of 72h study period
|
72 h after the initiation of enoxaparin
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical outcomes
Time Frame: 0-90 days after initiation of enoxaparin
|
Postoperative bleeding, DVT, pulmonary embolism, 90 day mortality
|
0-90 days after initiation of enoxaparin
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 290115-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on Enoxaparin
-
Indonesia UniversityPT Metiska FarmaCompleted
-
Oregon Health and Science UniversityNational Trauma Research Institute; Medical Research Foundation, OregonCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
University of OuluUniversity of HelsinkiUnknownIntracerebral HemorrhageFinland
-
Peking Union Medical College HospitalCompletedCoronary Artery Disease | Percutaneous Coronary InterventionChina
-
Lebanese American UniversityCompletedRenal Impairment | Venous ThromboembolismLebanon
-
PT Bio FarmaRecruiting
-
Portola PharmaceuticalsCompleted
-
University of UtahUniversity of MichiganCompletedSurgery | Venous Thromboembolism | Deep Venous ThrombosisUnited States
-
Wake Forest University Health SciencesTerminated